Inactive Instrument

ChemoCentryx, Inc.

CCXI

US16383L1061

ChemoCentryx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 01, 2022 at 04:39 pm EST

ChemoCentryx, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was USD 32.22 million compared to USD 64.89 million a year ago. Net loss was USD 131.76 million compared to USD 55.36 million a year ago.

Basic loss per share from continuing operations was USD 1.89 compared to USD 0.84 a year ago.

Latest news about ChemoCentryx, Inc.

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index	22-10-24	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index	22-10-24	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index	22-10-24	CI
Amgen Completes ChemoCentryx Acquisition	22-10-20	MT
Chemocentryx, Inc. Announces Executive Changes	22-10-20	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index	22-10-20	CI
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.	22-10-19	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index	22-10-19	CI
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	22-09-27	MT
Insider Sell: Chemocentryx	22-08-18	MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	22-08-18	MT
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
Stifel Cuts ChemoCentryx to Hold From Buy, Price Target to $52 From $86	22-08-10	MT
Insider Sell: ChemoCentryx	22-08-09	MT
Insider Sell: ChemoCentryx	22-08-09	MT
ChemoCentryx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
SVB Securities Downgrades ChemoCentryx to Market Perform From Outperform, Adjusts Price Target to $52 From $64	22-08-05	MT
HC Wainwright Downgrades ChemoCentryx to Neutral From Buy, Adjusts Price Target to $52 From $101	22-08-05	MT
Amgen Signals Additional $100 Million Hit to Revenue From Foreign Exchange Following Volume-Driven Second-Quarter Beat	22-08-05	MT
MarketScreener’s World Press Review : August 5, 2022	22-08-05
Canaccord Genuity Downgrades ChemoCentryx to Hold From Buy; Price Target is $52	22-08-05	MT
Healthcare Shares Slip Amid Deal News -- Healthcare Roundup	22-08-04	DJ
Amgen 2Q Profit Jumped After Write-Off From 2021 Acquisition	22-08-04	DJ
Sector Update: Health Care Stocks Slipping Ahead of Thursday Close	22-08-04	MT
Sector Update: Health Care	22-08-04	MT

Chart ChemoCentryx, Inc.

Duration

Period

More charts

Company Profile

ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The Company's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. It markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-3.82%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B

Biopharmaceuticals